JPMorgan Chase & Co. Has $6.30 Million Position in WAVE Life Sciences Ltd. $WVE

JPMorgan Chase & Co. lessened its holdings in shares of WAVE Life Sciences Ltd. (NASDAQ:WVE) by 45.2% in the third quarter, according to its most recent filing with the SEC. The firm owned 860,141 shares of the company’s stock after selling 708,874 shares during the period. JPMorgan Chase & Co. owned 0.51% of WAVE Life Sciences worth $6,296,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds also recently made changes to their positions in the business. Ameritas Investment Partners Inc. lifted its stake in shares of WAVE Life Sciences by 18.7% in the 2nd quarter. Ameritas Investment Partners Inc. now owns 11,444 shares of the company’s stock valued at $74,000 after purchasing an additional 1,802 shares during the period. Velan Capital Investment Management LP increased its holdings in WAVE Life Sciences by 15.4% in the second quarter. Velan Capital Investment Management LP now owns 15,000 shares of the company’s stock valued at $98,000 after purchasing an additional 2,000 shares during the last quarter. Matisse Capital increased its holdings in WAVE Life Sciences by 17.9% in the third quarter. Matisse Capital now owns 13,193 shares of the company’s stock valued at $97,000 after purchasing an additional 2,000 shares during the last quarter. Profund Advisors LLC lifted its stake in WAVE Life Sciences by 9.8% in the third quarter. Profund Advisors LLC now owns 24,722 shares of the company’s stock valued at $181,000 after buying an additional 2,215 shares during the period. Finally, Nebula Research & Development LLC lifted its stake in WAVE Life Sciences by 8.7% in the second quarter. Nebula Research & Development LLC now owns 34,342 shares of the company’s stock valued at $223,000 after buying an additional 2,748 shares during the period. Institutional investors own 89.73% of the company’s stock.

Analyst Ratings Changes

WVE has been the subject of several analyst reports. UBS Group set a $32.00 target price on WAVE Life Sciences in a research report on Tuesday, December 16th. Morgan Stanley set a $28.00 price target on shares of WAVE Life Sciences in a research report on Monday, December 8th. Oppenheimer lifted their price objective on shares of WAVE Life Sciences from $24.00 to $32.00 and gave the stock an “outperform” rating in a research note on Tuesday, December 16th. B. Riley Financial boosted their price objective on shares of WAVE Life Sciences from $19.00 to $37.00 and gave the company a “buy” rating in a report on Friday, December 12th. Finally, HC Wainwright reiterated a “buy” rating and issued a $30.00 target price on shares of WAVE Life Sciences in a report on Monday, March 2nd. One research analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $31.38.

WAVE Life Sciences Price Performance

NASDAQ WVE opened at $7.25 on Wednesday. The firm has a market cap of $1.36 billion, a P/E ratio of -5.94 and a beta of -1.77. The stock’s 50-day moving average is $12.66 and its 200-day moving average is $11.25. WAVE Life Sciences Ltd. has a one year low of $5.02 and a one year high of $21.73.

WAVE Life Sciences (NASDAQ:WVE) last issued its quarterly earnings data on Thursday, February 26th. The company reported ($0.30) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.28) by ($0.02). WAVE Life Sciences had a negative net margin of 478.35% and a negative return on equity of 85.69%. The business had revenue of $17.25 million during the quarter, compared to analyst estimates of $15.68 million. Equities analysts anticipate that WAVE Life Sciences Ltd. will post -1.14 EPS for the current year.

Insider Activity at WAVE Life Sciences

In other WAVE Life Sciences news, insider Chandra Vargeese sold 3,228 shares of the stock in a transaction dated Monday, February 9th. The stock was sold at an average price of $13.45, for a total transaction of $43,416.60. Following the completion of the transaction, the insider owned 408,246 shares in the company, valued at approximately $5,490,908.70. This represents a 0.78% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Paul Bolno sold 10,480 shares of WAVE Life Sciences stock in a transaction dated Monday, February 9th. The shares were sold at an average price of $13.45, for a total value of $140,956.00. Following the completion of the sale, the chief executive officer directly owned 275,520 shares in the company, valued at $3,705,744. This represents a 3.66% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold 61,748 shares of company stock worth $907,809 over the last three months. 23.98% of the stock is currently owned by insiders.

WAVE Life Sciences Profile

WAVE Life Sciences is a clinical-stage genetic medicines company focused on the discovery and development of stereopure oligonucleotide therapies designed to address serious diseases with high unmet medical need. Leveraging proprietary chemistry and precision synthesis, WAVE engineers drug candidates with defined stereochemistry to optimize potency, safety and manufacturability. This approach aims to enhance target specificity and improve therapeutic profiles compared with traditional oligonucleotide medicines.

The company’s pipeline includes programs in neuromuscular disorders such as Duchenne muscular dystrophy and neurodegenerative conditions including Huntington’s disease, as well as early-stage cardiovascular and liver indications.